Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients
- 20 February 2013
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 128 (2), 245-251
- https://doi.org/10.1016/j.ygyno.2012.11.023
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic MassObstetrics & Gynecology, 2011
- Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer PatientsInternational Journal of Gynecologic Cancer, 2011
- Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancerGynecologic Oncology, 2011
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus ConferenceInternational Journal of Gynecologic Cancer, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Symptom Control in Patients With Recurrent Ovarian Cancer: Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian CancerInternational Journal of Gynecologic Cancer, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Can Serum CA-125 Levels Predict the Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma?Gynecologic Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors1Biology of Reproduction, 1991